Latest Platform Technology News

FortifAI’s funding and big claims around faster AI data processing drove the week’s loudest move, while two small caps jumped on price queries. Elsewhere, results season rewarded clear recurring revenue growth, but punished gaps where early buying didn’t stick.

Fortifai Limited has launched a detailed roadmap for Nol8’s Agentic AI Data Plane technology, promising a dramatic leap in AI data processing speed and efficiency ahead of a commercial platform launch by the end of 2026.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

BetMakers Technology Group reported a robust Q2 FY26 with positive adjusted EBITDA and significant contract wins poised to fuel growth in the second half of the year.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

A wild week for small-cap tech, led by a price-query rocket in DTI and a heavy sell-off in Qoria despite strong recurring revenue growth. Cash receipts, contract wins and capital raises did most of the talking, while a few gap moves showed how fast early gains can vanish.

EPX Limited has successfully raised nearly $295,000 through a Security Purchase Plan, supporting its recent acquisition of Wattwatchers and positioning the company for further expansion.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

RocketDNA’s December quarter saw a robust 32% revenue jump, underpinned by new contracts with mining giants BHP and Anglo American, signalling strong momentum for 2026.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

Jayride Group Limited reports a reduced quarterly loss and secures fresh capital, yet faces ongoing uncertainty over its ability to continue as a going concern during its ASX reinstatement process.